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Background: The disease progression of cystic fibrosis (CF) is marked by an increase in clinical conditions and therapeutic interventions,
which have the potential to affect health-related quality of life (HRQoL). This cross-sectional study explored associations between clinical
variables and HRQoL.
Methods: HRQoL was measured using the Cystic Fibrosis Quality of Life (CFQoL) questionnaire, which consists of nine domains: physical,
social, treatment, chest symptoms, emotional functioning, concerns for the future, relationships, body image, and career concerns. The
CFQoL was completed by 223 adults with CF. Clinical and demographic data collected were: age, gender, FEV1% predicted, BMI,
Burkholderia cepacia status, lung transplant status, diabetic status, level of nutritional intervention, and presence of an intravenous access
device. Multiple regression using forward selection was used to construct models relating these variables to each HRQoL domain.
Results: Despite many of the variables being inter-related, some variables were associated with CFQoL domains even in the presence of
other important clinical factors. FEV1% predicted was weakly positively associated with all nine domains. Strong evidence emerged that
patients who had received a lung transplant reported a higher HRQoL in physical and social functioning, chest symptoms, and treatment
issues. Females tended to report a lower quality of life for chest symptoms and career issues, but higher values for body image. Patients with
an access device expressed more career concerns. There was no evidence of an association between B. cepacia and any of the nine CFQoL
domains. The model for the body image domain explained a high percentage of the variance (R2=30%): negative body image was associated
with lower BMI, having an access device, diabetes, and enteral feeding.
Conclusions: While important associations were identified, much of the variance in HRQoL remains unexplained. Other clinical and
psychosocial variables merit investigation. A longitudinal study is required to investigate how the disease trajectory and associated treatments
affect an individual’s quality of life.
D 2004 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
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Cystic fibrosis (CF) is the most common genetic fatal
disorder amongst Caucasian populations [1 2]. Approx-
imately 1 in 2000 live births is affected by the condition,1569-1993/$ - see front matter D 2004 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2004.12.005
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E-mail address: jabbott@uclan.ac.uk (J. Abbott).with 1 in 20 people carrying the recessive gene [2], which is
located in chromosome 7 [3]. The progression of cystic
fibrosis is typically one of reduced lung function, increased
pancreatic insufficiency (including the development of CF-
related diabetes), and the introduction of additional, and
sometimes invasive, treatment procedures. The late 1980s
saw the advent of the pan-antibiotic-resistant bacteria
Burkholderia cepacia [4], which has the potential to initiate
rapid pulmonary decline and death in some, whilst otherss 4 (2005) 59–66ed by Elsevier B.V. All rights reserved.
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pulmonary status. Within the adult CF population, there are
individuals at varying stages of the disease trajectory
experiencing different clinical conditions (e.g., diabetes, B
cepacia) and receiving different levels of interventions (e.g.,
nutritional support, access device). The progressive nature
of CF and the increasing treatment regimens have the
potential to encroach on daily living and to affect the
patients’ health-related quality of life (HRQoL).
Measurement of HRQoL has grown in importance over
the last three decades in a wide range of health-care
settings. HRQoL represents a comprehensive assessment of
the patients’ subjective responses to their disease status,
treatment interventions, and how these affect their every-
day lives [6]. HRQoL is typically measured using
questionnaires. The most common approaches to HRQoL
assessment are generic, disease-specific, and utility meas-
ures [7]. A discussion of the issues surrounding each type
of measurement is beyond the scope of the present paper,
but can be found elsewhere [8–11]. There is evidence that
better lung function is associated with higher reported
HRQoL in adolescents and adults with CF [12–14].
However, it is not clear what other demographic or clinical
variables are relevant to these patients’ life quality. This
work recorded age, gender, percentage of predicted forced
expiratory volume in 1 s (FEV1%), body mass index
(BMI), diabetes, B. cepacia, different levels of nutritional
intervention, intravenous (IV) access devices, and lung
transplant status. The aim of the study was to explore the
associations between these variables and domains of
HRQoL.1 Copies of the CFQoL and scoring equations are available from the
corresponding author as either hard copies or via e-mail.2. Method
2.1. Study design
This was a cross-sectional questionnaire study of patients
currently attending two regional cystic fibrosis centres.
Ethical approval was obtained to conduct the research at
both CF units.
2.2. Subjects
All patients attending the regional adult cystic fibrosis
centres in Manchester and Leeds were considered eligible
for the study. Over a 6-month period, all patients attending
the outpatient clinic at their respective centres were invited
to participate in the study.
2.3. Measures
Objective measurement of disease status comprised:
percentage of predicted forced expiratory volume in 1 s
(FEV1% predicted), body mass index (BMI), presence or
absence of diabetes, B. cepacia, or an intravenous (IV)access device fitted, and nutritional and lung transplant
status. Nutritional status was classified as: (a) having oral
supplements and a gastrostomy, (b) taking oral supplements
alone, or (c) no nutritional intervention. Lung transplant
status was classified: as (a) post-transplant, (b) on the
waiting list for transplant, or (c) those who, for whatever
reason, were not on the waiting list.
HRQoL was measured using the Cystic Fibrosis Quality
of Life (CFQoL) questionnaire.1 The CFQoL questionnaire
is a patient-derived disease-specific HRQoL measure that
has been fully validated [12,13]. It consists of 52 items
across nine domains of functioning: physical functioning,
social functioning, treatment issues, chest symptoms,
emotional functioning, concerns for the future, interper-
sonal relationships, body image, and career issues. Scores
are converted into values ranging from 0 (worst possible
quality of life) to 100 (best possible quality of life). Data
from routine clinical use suggest that a change of five
points on the CFQoL scales indicates a small, meaningful
change as perceived by the patient. It is more difficult to
assess the magnitude of clinically important differences
between individuals, although one would expect these to
be greater. Differences of seven to eight points between
groups are likely to be clinically important; differences of
10 points would definitely be regarded as being clinically
important.
2.4. Procedure
Patients were given a copy of the Cystic Fibrosis
Quality of Life (CFQoL) questionnaire [12] to complete
and return via the mail in a pre-paid envelope. Respond-
ents were asked to return the questionnaire within 1 week
of attending clinic. Patients were instructed to record the
date of completion on the questionnaires. This process
indicated that all questionnaires in the study had been
returned within 1 week of attendance at clinic. All other
variables were recorded on the day patients attended
clinic.
2.5. Statistical analysis
Because of the skewness of the data, descriptive statistics
for each group across clinical and demographic indicators
and CFQoL domains are represented as median values and
inter-quartile range (25th and 75th percentiles). The main
method of analysis was multiple regression. However, such
models can be difficult to interpret when predictor variables
are themselves inter-associated (e.g., those patients with
diabetes are also likely to have an access device). For this
reason, these inter-associations were also described. For
each HRQoL domain, an initial exploratory analysis using a
L. Gee et al. / Journal of Cystic Fibrosis 4 (2005) 59–66 61simple linear model was carried out to examine possible
associations with each variable. A forward selection
regression method was then used, employing the set of
variables identified by the initial simple analysis. Given the
associations between potential predictor variables, and the
clinical relevance of FEV1% predicted, this variable was
always entered first into the regression analysis. A
significance level of 0.10 was used as a guide for the
inclusion/exclusion of variables. Two-way interactions were
also investigated. Multiple regression analysis was carried
out using SPSS version 10.
Regression models require that the residuals of the data
being modelled should be normally distributed with
constant variance. Where these assumptions are not met,
the usual estimates of variability, and hence p-values, are
unreliable. For data where such requirements are not met,
it is sometimes possible to transform the data by applying
a mathematical function to the response variable. If no
transformation is effective, then a method called boot-
strapping can be used. Bootstrapping is a method of re-
sampling from the observed data in order to estimate
variability in parameter estimates. Models were checked by
examining residual plots, checking for influential observa-
tions, and confirming that the model would not be
significantly improved by the inclusion of any of the
other variables. All final models on the original untrans-Table 1
Median values and inter-quartile range (25th and 75th percentiles) for percentage
across each of the clinical status groups
Group n FEV1% B
Gender
Male 102 58.4 (40–77)
Female 121 48.9 (34–69)
Cepacia
No 198 53.1 (36–75)
Yes 25 49.8 (39–64) 2
Diabetes
No 174 55.3 (41–77) 2
Yes 49 40.5 (30–59)
Access device
No 160 60.6 (42–79) 2
Yes 63 40.7 (29.5–54)
Nutritional status
No intervention 103 64.3 (43–81) 2
Oral supplements 92 53.4 (33–67)
Oral supplements+gastrostomy 28 35.9 (24–44) 1
Transplant status
Not on waiting list 196 53.7 (40–73) 2
Waiting list 13 21.8 (20–27) 1
Post-transplant 14 77 (46–83)
Values presented throughout are medians and (inter-quartile range) unless other
volume in 1 s; BMI=body mass index; n/a=not applicable.formed scales were checked using the bootstrap facility in
Stata 6.0 using 1000 replications.3. Results
3.1. Descriptive statistics
Two hundred and twenty-three patients returned ques-
tionnaires within a week of attending clinic. This
represented an overall response rate of 57%. A comparison
between non-responders and responders has been previ-
ously reported in detail for this sample [13]. This indicated
that there were no important differences either statistically
or clinically between responders and non-responders for
age, FEV1% predicted, or BMI. The average time between
attendance at clinic and completion of the questionnaire
was 3 days. Mean FEV1% predicted of the total sample
was 55% predicted (standard deviation [S.D.]=23.5%),
mean BMI was 20.8 (S.D.=2.5), whilst the mean age was
25.1 years (S.D.=7.1 years). Of the total sample, the male-
to-female ratio was 102:121. Detailed information out-
lining median values and inter-quartile ranges (25th and
75th percentiles) for each of the potential predictor
variables across demographic and clinical indicators is
presented in Table 1.of predicted FEV1, body mass index (BMI), age, and gender distribution
MI Age Gender (n and % males
in each group)
21 (20–22) 24.5 (20–29) n/a
20 (19–22) 23.0 (19–29) n/a
20 (19–22) 24 (19–29) 88 (44.5%)
0.2 (19–21) 21 (18–26) 14 (56.0%)
0.5 (19–22) 23.5 (19–29) 85 (49.0%)
20 (19–22) 26 (19.5–29.5) 17 (34.5%)
1.1 (19–22.5) 26 (20–30) 88 (55.0%)
20 (18.8–21) 22 (19–27) 14 (22.0%)
1.6 (20–23.5) 26 (20–30) 35 (34.0%)
20 (19–21) 24.5 (19–29) 57 (62.0%)
8.7 (17–20) 20 (18–23) 10 (35.7%)
0.4 (19–22) 24 (19–29) 93 (47.5%)
8.4 (17–19) 21 (19–26) 1 (8.0%)
21 (19–23) 28.5 (24–32) 8 (57.0%)
wise stated; n=number in group; FEV1%=percentage of forced expiratory
Table 2
Median values and inter-quartile range (25th and 75th percentiles) for each group across CFQoL domains
n PF SF TI CS EF FC IR BI CI
Gender
Male 102 94 (76–98) 95 (80–100) 86 (71–93) 80 (50–90) 87 (75–95) 46 (26–66) 63 (45–78) 60 (45–80) 65 (40–90)
Female 121 88 (67–98) 95 (70–100) 80 (53–93) 70 (40–80) 82 (65–92) 40 (26–56) 68 (46–80) 73 (53–93) 55 (32–80)
Cepacia
No 198 90 (72–98) 95 (75–100) 80 (60–93) 70 (50–90) 85 (69–92) 43 (26–63) 66 (46–80) 66 (46–86) 60 (38–85)
Yes 25 92 (74–96) 95 (80–100) 73 (43–93) 70 (50–80) 82 (65–91) 46 (28–60) 68 (48–79) 60 (36–80) 60 (40–82)
Diabetes
No 174 92 (76–98) 95 (80–100) 80 (60–93) 75 (50–90) 85 (69–92) 46 (26–63) 66 (46–80) 66 (46–86) 62 (40–85)
Yes 49 84 (66–94) 95 (67–100) 80 (53–93) 60 (30–80) 85 (66–93) 36 (23–56) 66 (44–75) 60 (40–80) 50 (32–77)
Access device
No 160 94 (78–98) 95 (81–100) 86 (66–98) 80 (50–90) 87 (70–95) 45 (26–63) 68 (48–82) 66 (46–86) 70 (45–90)
Yes 63 80 (66–94) 90 (65–100) 73 (46–86) 60 (30–80) 77 (65–90) 40 (23–53) 60 (42–74) 60 (40–80) 40 (25–60)
Nutritional status
No intervention 103 92 (76–98) 95 (80–100) 86 (60–100) 80 (50–90) 87 (70–92) 46 (26–63) 68 (52–84) 80 (60–93) 65 (45–90)
Supplements 92 91 (70–98) 95 (80–100) 80 (61–93) 70 (50–90) 85 (67–92) 43 (26–60) 66 (46–78) 60 (41–73) 60 (35–80)
Supplements+gastrostomy 28 79 (66–92) 90 (65–100) 70 (53–86) 60 (32–80) 78 (65–92) 43 (24–63) 55 (40–74) 50 (40–60) 42 (30–75)
Transplant status
Not on waiting list 196 91 (76–98) 95 (80–100) 80 (60–93) 70 (50–90) 85 (67–92) 43 (26–62) 66 (46–80) 66 (46–86) 60 (40–85)
Waiting list 13 66 (55–75) 70 (52–90) 53 (40–70) 50 (30–70) 75 (48–87) 33 (21–61) 52 (39–74) 60 (36–73) 35 (27–62)
Post-transplant 14 96 (92–100) 95 (93–100) 96 (91–100) 100 (77–100) 91 (82–98) 51 (25–66) 62 (39–74) 66 (45–75) 37 (33–75)
Values presented throughout are medians and (inter-quartile range) unless otherwise stated; n=number in group; PF=physical functioning; SF=social functioning; TI=treatment issues; CS=chest symptoms;



































L. Gee et al. / Journal of Cystic Fibrosis 4 (2005) 59–66 63Details of median values and interquartile ranges (25th
and 75th percentiles) for the potential predictor variables
across each domain of the CFQoL are outlined in Table 2.
3.2. Associations between the clinical variables
Most explanatory variables were inter-related. For the
purpose of this study, the relevant associations are those
between the variables that seem important from the
simple regression analyses, and also FEV1% predicted
because of its clinical importance. There was a modest
positive correlation between FEV1% predicted and BMI
(r=0.39) and a small positive correlation between age and
BMI (r=0.27). Diabetics and patients with an access
device tended to have a lower average FEV1% predicted,
as did those on the waiting list for transplant. Post-
transplant patients tended to have a higher average
FEV1% predicted, as did those who were not prescribed
nutritional supplements. Patients on the transplant waiting
list or on enteral feeds (these often occurred together)
tended to have an access device. Diabetic patients were
more likely to be on the transplant waiting list or to have
had a transplant, and more likely to be on enteral feeds.
Females were more likely to be on the waiting list for
transplant, were less likely to be taking oral supplements,
but more likely to have an access device. In contrast, B.
cepacia was not associated with any other clinical
variable.
3.3. Regression analyses between potential explanatory
variables and CFQoL domains
Simple linear regression suggested potential explana-
tory variables for each CFQoL domain. These results,
together with a summary of the multiple regression
analyses, are given in Table 3. The beta estimates should
be interpreted with caution because of the inter-relation-
ships between variables. For example, a change from
being on a transplant waiting list to post-transplant would
be accompanied by a large increase in FEV1% predicted,
which in itself would be accompanied by an increase in
HRQoL (see worked example in the footnote of Table 3).
FEV1% predicted was positively correlated with all
HRQoL domains, but explained only a small proportion
of variability. Indeed, for most HRQoL domains, only a
small proportion of the variability in scores was explained
by the set of clinical variables. The models that best
explained HRQoL (in terms of R2) were those for physical
functioning and body image.
There was strong evidence that post-transplant status
had important clinical implications for quality of life.
Subjects who were post-transplant tended to report a
much higher quality of life for physical functioning,
social functioning, treatment issues, and chest symptoms.
In some domains, gender also appeared to be important,
with females reporting higher scores for body image andlower scores for chest symptoms and emotional function-
ing. Individuals with an access device tended to have
more career concerns. There was no evidence of any
association between B. cepacia and any of the CFQoL
domains.
The aspect of HRQoL that was best explained was body
image (R2=30%), although it was difficult to identify the
most appropriate model. Body mass index and gender
were clearly important: females and those with higher BMI
reported a more positive body image. Those with diabetes,
on enteral feeds, or having an access device tended to
report a more negative body image, although a model
including any two of these three variables was potentially
acceptable.4. Discussion
Many of the clinical variables were inter-related. This is
not surprising, as the majority of them would be expected
to be present as a function of deterioration in disease
status. For example, it would be anticipated that FEV1%
predicted and BMI would both deteriorate as a function of
disease progression; alongside this there would be an
increased incidence of diabetes, access devices, increased
nutritional interventions, and the likelihood of being on the
transplant list. The interest of this study was whether,
despite these inter-relationships, any particular variables
were associated with CFQoL domains even in the presence
of the other important clinical factors.
Although FEV1% is an important indicator of disease
status and does have some positive association with all
nine domains of the HRQoL instrument, the beta estimates
are not high and so very large differences in FEV1%
predicted would be required to predict even modest
differences in HRQoL scores. In general, only a small
proportion of variability in HRQoL scores was explained
by the models. These results are consistent with previous
studies. Weak to moderate correlations between FEV1%
predicted and HRQoL have been shown for domains
reflecting psychosocial issues [12–17]. Staab et al. [17]
demonstrated that only 14% of the variance in quality of
life was explained by Swachman score, FEV1, and
percentage of ideal body weight.
Transplant status is clearly highly relevant to quality of
life in adults with cystic fibrosis. This is predominantly
true for those domains more strongly related to functional
health status (physical and social functioning, chest
symptoms, and treatment issues). This is not surprising
given that transplantation marks the most radical inter-
vention in terms of clinical improvement. However,
patients not on the transplant waiting list are a heteroge-
neous group comprising those with no medical need for
transplant, those who may have decided against a trans-
plant, and those refused transplantation. This may have
diluted the most striking effect in HRQoL for a CF
Table 3





Beta estimates (95% CI) R2 (%)
Physical functioning FEV1% FEV1% 0.20 (0.11, 0.29) 18.7
Age Age 0.44 (0.80,0.10)
Gender Transplant status
Diabetic status Not on waiting list 0
Transplant status On waiting list 15 (29, 3.5)
Access device Post-transplant 8.2 (0.93, 14)
Social functioning FEV1% FEV1% 0.12 (.004, 0.25) 6.3
Transplant status Transplant status
Access device Not on waiting list 0
On waiting list 12.7 (32, 0.09)
Post-transplant 7.3 (0.36,13)
Treatment issues FEV1% FEV1% 0.17 (0.03, 0.32) 8.4
Transplant status Transplant status
Access device Not on waiting list 0
On waiting list 10 (23, 5.4)
Post-transplant 16 (6.0, 23)
Chest symptoms FEV1% FEV1% 0.29 (0.14,0.43) 14.8
Gender Gender
Diabetic status Male 0
Transplant status Female 8.7 (15,1.8)
Access device Transplant status
Not on waiting list 0
On waiting list 1 (16, 16)
Post-transplant 20 (10, 28)
Emotional functioning FEV1% FEV1% 0.14 (0.02, 0.24) 6.6
Gender Gender
Male 0
Female 5.8 (11, 1.7)




Interpersonal relationships FEV1% FEV1% 0.18 (0.06, 0.30) 3.8
Nutritional status
Access device
Body image FEV1% FEV1% 0.10 (0.05,0.23) 30.0
BMI BMI 3.4 (2.1, 4.6)
Gender Gender
Diabetic status Male 0
Nutritional status Female 14 (7.9, 20)
Access device Diabetic statusa
Not diabetic 0
Diabetic 6.1 (12.8, 0.30)
Nutritional statusa
No supplements 0
Oral supplements 5.4 (12.4, 1.6)
Oral supplements+gastrostomy 8.7 (18, 2.6)
Access devicea
No device 0
Device fitted 3.7 (11, 3.2)
Career concerns FEV1% FEV1%
b 0.11 (0.05, 0.30) 12.4
Age Age 0.67 (1.24, 0.20)
Gender Access device
Diabetic status No device 0
Nutritional status Device fitted 18 (27, 9.4)
Transplant status
Access device
L. Gee et al. / Journal of Cystic Fibrosis 4 (2005) 59–6664intervention. Marked improvements in well-being have
been previously reported in pre–post studies of heart–lung
and lung transplantation [18 19].Gender differences exist for some aspects of HRQoL.
Females tended to report lower scores for chest symptoms
and emotional functioning. Females also tended to have a
L. Gee et al. / Journal of Cystic Fibrosis 4 (2005) 59–66 65more positive body image than males. This has been noted
by Abbott et al. who reported that females with CF were
happy with their lean body shape, possibly because of
cultural desirability, whereas males preferred to be much
heavier [20].
Having an access device did not emerge from the
analysis as being particularly associated with the majority
of CFQoL domains in the presence of other variables.
However, those patients with an access device reported
more concerns regarding their careers and a more negative
body image. A recent study has described patients’ concerns
and problems about the site of insertion of access devices
[21]. In the current sample, two-thirds of patients had the
device fitted in the arm and the remaining one-third had it
placed in the chest. Given that the device has the potential to
have a negative effect on HRQoL, patient choice regarding
the site of the device is important. It was not possible with
these data to determine whether it was the presence or the
site of the device that was the cause of concern.
It may be anticipated that having B. cepacia would have
a negative effect on HRQoL as it brings further uncertainty
about the future. The present data provide no evidence that
the group of patients with a diagnosis of B. cepacia had
significantly different scores in any domain of HRQoL. B.
cepacia was not associated with any of the CFQoL variables
either in univariate analyses or after controlling for other
significant variables. This may be counter-intuitive given
that these patients are routinely informed that they have B.
cepacia and then segregated from non-cepacia patients at
clinic, on wards, and at scientific meetings. It is also
incongruent with the view expressed in a recent paper [22],
which suggested that the act of segregating and isolating CF
patients with B. cepacia might lead to psychological
impairments across a number of areas including HRQoL.
Recent work suggests that there may be a differential
pathogenic potential of various B. cepacia multivars [23].
However, it is impossible to assess the effect of this on
HRQoL in the present sample, as such data were not
collected. However, all patients had been colonized for at
least 1 year. This suggests that even if there had been some
negative psychological effect at diagnosis, participants had
adapted to the knowledge and the consequences of living
with B. cepacia.
So far the discussion has concentrated on the relative
importance of the clinical variables with respect to aspects
of HRQoL. Given that the regression model for the body
image domain of the CFQoL explained a high percentage ofNotes to Table 3:
Beta estimates are used in the following way. Consider an individual with FEV1% p
age with FEV1=20 who is on the waiting list. The difference in their predicted
(difference in FEV1)0.20 (beta estimate for FEV1)=10 together with 8.2{1
waiting list).
R2=the percentage of variance explained by the variables present in each regression
BMI=body mass index.
a Any two of these three jointly significant.
b Not significant in the presence of age.the variance, this merits consideration. Patients with greater
levels of nutritional intervention or lower BMIs reported a
poorer body image. The relative importance of nutritional
status, diabetic status, and access device was complex, as
models including any two of these three factors seemed
acceptable. These factors all include an invasive element
that may have a negative effect on body satisfaction.
Previous work has shown that body image is extremely
important to adolescents and adults with CF [20,24–28], and
a scale has been recently developed to assess the attitudes to
body image in CF [27]. A greater understanding of how CF
patients perceive their body image is very important as it
can influence motivation to adhere to treatments and
potentially survival [20,27].
A weakness of the study is the response rate of 57% and
the potential bias that this may introduce. However, this
response rate is comparable with that of other CF
questionnaire-based research [15,28]. While the responders
and non-responders were clinically similar, it is impossible
to assess the representativeness of the sample in terms of
psychosocial characteristics. Although the sample size was
relatively large for CF research, it may not have been large
enough to detect the complexities in the relationships. For
example, variables that were significant in the simple
analysis but not in the multiple regression analysis might
be shown to be important in a larger study, or there may be
important interactions between the clinical variables. None-
theless, this study contributes to the existing knowledge
about HRQoL in adolescents and adults with CF. It is the
first study to consider a set of key clinical variables and to
assess which of these, in the presence of the others, has
particular importance to HRQoL.
This cross-sectional study has investigated differences
between individuals but could not evaluate changes over
time. A longitudinal study would be needed to explore such
effects and might yield different results. For example,
changes in FEV1% predicted might be more strongly
associated with changes in reported HRQoL at an individual
level. In considering directions for further research, it is
likely that other clinical and psychosocial variables, not
studied here, would affect quality of life. For example, data
were not collected on the length of time individuals had
lived with diabetes, an access device, or a transplant.
Additionally, there is a need to investigate the impact of
specific treatment protocols on treatment adherence and
quality of life. Psychosocial factors such as coping
strategies, locus of control, or social support may also beredicted=70 who is post-transplant compared with an individual of the same
scores on the physical functioning scale is 33.2. This is calculated by 50
5}=23.2 (the difference between the beta estimates for post-transplant and
analysis. FEV1% predicted=percentage of forced expiratory volume in 1 s;
L. Gee et al. / Journal of Cystic Fibrosis 4 (2005) 59–6666important. All of these factors need to be considered in order
to provide greater insight into the demands created by the
CF disease trajectory and its treatments and their effects on
quality of life.References
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